跳至主要内容
临床试验/EUCTR2009-013103-63-DE
EUCTR2009-013103-63-DE进行中(未招募)不适用

Pilot study investigating the effect of intra-coronary and intra-myocardial application of enriched CD133pos autologous bone marrow derived stem cells for improving left ventricular function in chronic ischemic cardiomyopathy - AlsterMACS

Asklepios Kliniken Hamburg GmbH0 个研究点目标入组 64 人开始时间: 2011年4月21日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
64

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients 18 to 80 years old
  • of female and male gender
  • Patient has reduced ejection fraction as evaluated by routine clinical angiogramm,
  • echocardiography or MRI (=45%) due to ischemic heart disease
  • symptomatic heart failure NYHA = II on optimal therapy
  • coronary artery in the target region that can be used for cell infusion
  • Patient has been informed of the nature of the clinical trial and agrees to its provision and
  • has provided written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • planned or performed CABG surgery or PCI within 4 weeks of study entry
  • recent myocardial infarction (< 6 months)
  • TIMI flow < II in the coronary artery selected for infusion
  • cardiogenic shock requiring mechanical ventilation or intra-aortic balloon pump
  • progressive tumor disease
  • primary disease of bone marrow including mal-function of components of the coagulation
  • women of child-bearing age premenopausal
  • LV wall thickness < 5mm at planned site of injection
  • ventricular wall thrombus
  • severe aortic valvular heart disease
  • severe atrial or ventricular tachycardia unresponsive to intravenous or oral drug therapy
  • aneurysm of the anterior wall
  • history of stroke
  • know diseases of the liver resulting in reduced plasmatic coagulation with spontaneous INR
  • patients with chronic infectious diseases (HBV, HCV, HIV)
  • patients taking part or have taken part in other clinical trials within the past 3 months
  • patients unable to provide informed consent
  • any other medical condition that the enrolling physician deems significant in representing a
  • potential hazard for the patient when participating in this study

研究者

相似试验